Abbott seeks Humira psoriasis claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott submits an sBLA for its tumor necrosis factor inhibitor Humira (adalimumab) for treatment of moderate to severe chronic plaque psoriasis, the company announced April 2. The submission is based on the results of two double-blind, placebo-controlled trials of Humira - REVEAL and CHAMPION - evaluating the biologic based on the Psoriasis Area and Severity Score. The 52-week REVEAL study evaluated more than 1,200 patients with moderate to severe chronic plaque psoriasis, for which 71 percent achieved PASI 75 or better compared to 6.5 percent on placebo. The 16-week CHAMPION study evaluated 271 patients; 80 percent of patients treated with Humira achieved PASI 75 or better compared to 36 percent treated with methotrexate. Humira gained a Crohn's indication Feb. 27, making it the first self-administered biologic approved for Crohn's (1Pharmaceutical Approvals Monthly March 2007, In Brief). The biologic is also approved for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis...
You may also be interested in...
Abbott looking beyond anti-TNF agents for psoriasis
Abbott plans to initiate a Phase III study of its fully human monoclonal antibody ABT-874 for psoriasis later this year, pending FDA feedback, the firm announces May 4. Targeting interleukin-12 and interleukin-23, the biologic could potentially be a first-in-class treatment for psoriasis. A previous 12-week, double-blind, placebo-controlled Phase II study enrolled 180 patients with moderate to severe psoriasis. Results showed that ABT-874 was significantly more effective than placebo, with 90 percent of patients achieving 75 percent improvement in the degree and severity of skin lesions in four of the five active treatment groups. Abbott's tumor necrosis factor inhibitor Humira (adalimumab) is pending at FDA for moderate to severe chronic plaque psoriasis (1Pharmaceutical Approvals Monthly April 2007, In Brief)...
Humira cleared for Crohn’s
Abbott's tumor necrosis factor inhibitor Humira (adalimumab) gained a Crohn's indication from FDA Feb. 27, and may offer a potential benefit over J&J's Remicade (infliximab) as the first self-administered biologic approved for Crohn's disease. Humira is administered subcutaneously every other week, while Remicade requires an infusion. Previously approved for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Humira's new indication is for reducing the signs and symptoms and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have an inadequate response to conventional therapy. Abbott expects Humira to generate peak sales of $500 million in the Crohn's disease indication. UCB had hoped to beat Humira to approval with its Crohn's candidate Cimzia, but received a "complete review" letter from FDA in December (1Pharmaceutical Approvals Monthly January 2007, p.19)...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.